Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Gains from Sales and Divestitures (2022 - 2024)

Historic Gains from Sales and Divestitures for Bolt Biotherapeutics (BOLT) over the last 3 years, with Q4 2024 value amounting to $41713.0.

  • Bolt Biotherapeutics' Gains from Sales and Divestitures fell 2812.32% to $41713.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $41713.0, marking a year-over-year decrease of 2812.32%. This contributed to the annual value of $41713.0 for FY2024, which is 2812.32% down from last year.
  • According to the latest figures from Q4 2024, Bolt Biotherapeutics' Gains from Sales and Divestitures is $41713.0, which was down 2812.32% from $58034.0 recorded in Q4 2023.
  • Bolt Biotherapeutics' 5-year Gains from Sales and Divestitures high stood at $80533.0 for Q4 2022, and its period low was $41713.0 during Q4 2024.
  • Its 3-year average for Gains from Sales and Divestitures is $60093.3, with a median of $58034.0 in 2023.
  • In the last 5 years, Bolt Biotherapeutics' Gains from Sales and Divestitures tumbled by 2793.76% in 2023 and then tumbled by 2812.32% in 2024.
  • Over the past 3 years, Bolt Biotherapeutics' Gains from Sales and Divestitures (Quarter) stood at $80533.0 in 2022, then dropped by 27.94% to $58034.0 in 2023, then fell by 28.12% to $41713.0 in 2024.
  • Its last three reported values are $41713.0 in Q4 2024, $58034.0 for Q4 2023, and $80533.0 during Q4 2022.